Business Context and Reporting Period
This Form 6-K filing by Quoin Pharmaceuticals Ltd. covers the month of April 2022, specifically addressing a notification received on April 22, 2022, from The Nasdaq Stock Market, LLC. The Company is a foreign private issuer headquartered in Tel Aviv, Israel.
Key Financial Metrics
The filing does not provide specific historical financial statements, revenue, profit, or cash flow figures for the reporting period. However, it highlights the following financial status indicators:
- Stockholders' Equity: The Company failed to meet the Nasdaq minimum requirement of $2.5 million as of April 21, 2022.
- Market Value/Net Income: The Company also failed to meet alternative listing requirements based on market value of listed securities or net income from continuing operations.
- Expected Funding: The Company anticipates gross proceeds of approximately $9.5 million from Altium Growth Fund, LP.
Material Changes and Listing Status
The primary material change is the loss of compliance with Nasdaq Capital Market listing standards. Specifically:
- The Company received a deficiency notice regarding Nasdaq Rule 5550(b)(1) (minimum stockholders' equity).
- The Company has 45 calendar days (until June 6, 2022) to submit a plan to regain compliance.
- If a plan is accepted, Nasdaq may grant an extension of up to 180 calendar days to evidence compliance.
- The notification has no immediate effect on the Company's current listing status.
Outlook, Management Commentary, and Risks
Management is actively working on a plan to regain compliance, centered on securing additional funding. Key points include:
- Funding Strategy: The Company is in discussions with Altium Growth Fund, LP regarding the mandatory exercise provision of a Series C Warrant issued in March 2022.
- Contingency Plan: If the warrant exercise requirements are not met, Altium has committed to provide funding equal to the expected $9.5 million proceeds at prevailing market rates.
- Compliance Expectation: Management believes the receipt of approximately $9.5 million is likely to satisfy the $2.5 million stockholders' equity requirement.
- Risks: There is no assurance that the funding will be received or that the Company will successfully regain compliance. Actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the status of discussions with Altium Growth Fund, LP regarding the $9.5 million funding commitment.
- Confirm whether the mandatory exercise provision of the Series C Warrant has been triggered or if the alternative funding commitment is being executed.
- Monitor the submission of the compliance plan to Nasdaq by the June 6, 2022 deadline.
- Review the Company's Annual Report on Form 20-F (filed April 14, 2022) for detailed risk factors and historical financial data not included in this 6-K.